Findings from a biomarker analysis of the phase 3 AtTEnd trial (NCT03603184) indicate that high whole-exome sequencing (WES)–aneuploidy scores (W-AS) may serve as a...
Genentech has reported significant findings from its Phase III IMvigor011 study, which evaluated the efficacy of its drug, Tecentriq (atezolizumab), as an adjuvant treatment...
The treatment landscape for hepatocellular carcinoma (HCC) is evolving, particularly with the refinement of first-line immunotherapy strategies. In a recent discussion on the podcast...